Your Hair Is Thinning on Hormone Therapy. Testosterone Isn't Always the Reason.
More hair in the shower drain, a part that looks wider than it did a year ago, strands on the pillow in the morning. If this started after you began hormone therapy, it's easy to land on one explanation: it's the testosterone, and the dose needs to come down. Sometimes that's true. Often it isn't, and treating it like a single-cause problem, either by cutting a dose that was actually helping everything else, or by ignoring it and hoping it resolves on its own, usually means missing what's actually driving it.
Two Kinds of Hair Loss That Get Confused With Each Other
Diffuse shedding and pattern thinning look similar in the shower but come from different mechanisms, and the distinction matters because the workup and treatment aren't the same.
Telogen effluvium is diffuse: hair falling out all over the scalp, usually a delayed reaction to something that happened two to three months earlier, an illness, a crash diet, a major stressor, or a hormonal shift. It's the growth cycle getting interrupted, not destroyed. Androgenetic thinning follows a pattern instead, typically widening at the part and thinning at the crown, driven by androgen exposure at the follicle causing individual hairs to grow back progressively finer, a process called miniaturization. The two aren't mutually exclusive. A woman starting testosterone therapy can have both at once, which is exactly why "just lower the dose" doesn't always fix it.
The Causes That Get Overlooked Before Anyone Blames the Hormone
Several common, correctable drivers of diffuse shedding get skipped over when testosterone is the newest variable in the picture and the easiest thing to point at.
Thyroid function is one of the most common, and both an underactive thyroid and, less often, an overactive one can trigger it, even when TSH sits inside the standard reference range, since TSH reflects pituitary signaling rather than what's actually available to your tissues. Ferritin, your iron storage protein, is another: hair follicles are metabolically demanding tissue, and low iron stores can trigger shedding well before you're anemic enough to show it on a standard CBC. Not being anemic and having adequate ferritin for hair growth are not the same threshold.
Cortisol and chronic stress matter too, and because of the roughly three-month lag between a major stressor and the shedding it can trigger, the connection often gets missed entirely. Estrogen decline plays a role independent of testosterone, since estrogen helps prolong the growth, or anagen, phase of the hair cycle, so the drop of perimenopause and menopause can itself produce diffuse thinning. Zinc, vitamin D, and adequate protein intake round out the list, inexpensive to check and correct, and easy to overlook once a newer hormone is in the picture.
None of this rules out DHT as a contributor. It means DHT shouldn't be the first, or only, explanation reached for.
Why Some Women Are More Sensitive to DHT Than Others
When androgen-driven, pattern-type thinning is genuinely present, the next question is usually: why does one woman on a given testosterone dose thin noticeably while another woman on the same dose doesn't? The honest answer is genetics, and it's more interesting, and more limited, than most of what circulates about it online.
Testosterone itself isn't what acts on the hair follicle. A local enzyme, 5-alpha-reductase, converts testosterone to dihydrotestosterone, DHT, right at the follicle, and DHT binds the follicle's androgen receptor far more potently than testosterone does. Two women with identical serum testosterone can have very different DHT exposure at the scalp, because it's local conversion efficiency, not the blood level, that determines what the follicle actually sees.
Two genes shape that local sensitivity. The androgen receptor, AR, gene sits on the X chromosome, so women carry two copies, and which copy gets preferentially expressed, a process called X-inactivation, can skew the follicle toward a more or less androgen-sensitive receptor regardless of circulating hormone levels. The largest genetic study of androgenetic alopecia to date identified variation within the AR gene itself as the major determinant of the condition (Hillmer AM et al., 2005 — PMID: 15902657), a study conducted in men with early-onset pattern baldness, but one that established the AR gene's central role in the same receptor women carry. Separately, genetic variants in SRD5A1, the isoenzyme responsible for local conversion, have been linked to the degree of hirsutism in women with polycystic ovary syndrome, suggesting SRD5A1, not SRD5A2, is the more relevant isoform at androgen-sensitive follicles (Goodarzi MO et al., 2006 — PMID: 16849416).
That biology is well supported for androgen sensitivity broadly. It hasn't been validated specifically for female pattern hair loss: one study that directly tested SRD5A1, SRD5A2, and the estrogen and progesterone receptor genes in nearly 200 women with pattern hair loss found no significant association with any of them (Redler S et al., 2012 — PMID: 22509838). No study has tested whether this genotype predicts who thins on testosterone therapy, or at what dose. A genetic panel marketed as predicting your personal DHT threshold is extrapolating from adjacent biology, not reporting a validated result. Individual DHT sensitivity is real and independent of dose. It's a reasonable explanation for why two women on the same regimen have different outcomes, even without a test that can tell you in advance which one you are.
How to Actually Find Out What's Driving It
A real workup starts by ruling the overlooked causes in or out: TSH alongside free T3, ferritin, vitamin D, recent stressors, and diet. If those are clear and the pattern looks androgenetic rather than diffuse, DHEA-S, free and total testosterone, and SHBG characterize the androgen picture, though they won't predict follicular sensitivity directly.
A blood DHT level seems like the obvious next test, and it's usually not a useful one. Serum DHT reflects conversion happening throughout the body, not conversion happening locally at your follicle, so it doesn't tell you what the follicle itself is actually exposed to. And even a genuinely elevated follicular DHT level wouldn't answer the more important question, since it's the androgen receptor's sensitivity, not the DHT concentration in front of it, that determines whether a given follicle responds. A normal serum DHT doesn't rule out androgen-driven thinning, and an elevated one doesn't confirm it either. A scalp exam, sometimes with trichoscopy, is what actually distinguishes a diffuse process from a patterned one, information no blood panel can give you.
Two women can have identical bloodwork and completely different amounts of hair loss. That gap is follicular biology, not a measurement error, and it's exactly why treating by symptom response matters more than chasing a population-average safe dose.
A Familiar Pattern
A patient in her late forties started testosterone therapy for low energy and low libido, both of which improved within weeks. Three months in, more hair on her pillow and in the shower drain had her convinced the testosterone needed to stop. Her labs told a different story: ferritin was low-normal, and her free T3 sat at the bottom of the range despite a normal TSH. Addressing both directly, alongside continuing her testosterone at the same dose, resolved the shedding over the following months without giving up the benefits she'd already gained.
What Can Be Done
Once the overlooked causes are addressed, several options exist for hair loss that's genuinely androgen-driven, and they aren't mutually exclusive.
Minoxidil, topical or in low-dose oral form, remains the best-studied option and a reasonable starting point regardless of underlying cause. Pairing it with microneedling improves results over minoxidil alone (Ahmed KMA et al., 2025 — PMID: 40056230). Platelet-rich plasma, PRP, scalp injections use your own concentrated platelets to stimulate the follicle directly, with modest but real improvements in hair density and count in women (de Oliveira AFQ et al., 2023 — PMID: 36264022).
Spironolactone and finasteride or dutasteride, taken orally or applied topically, work by blocking androgen activity at different points and are used off-label for female pattern hair loss. One important safety point regardless of route: finasteride and dutasteride carry a pregnancy contraindication because of demonstrated risk to a male fetus, which applies to any woman who could become pregnant, not only those currently trying to conceive.
Nutraceutical blends like Nutrafol, among other similar formulations on the market, are another option many patients find helpful, with a randomized, placebo-controlled trial showing improvement in hair growth over placebo in women with thinning hair (Ablon G, Kogan S, 2018).
Scalp microneedling paired with topical exosome application, offered in my own practice as a topical adjunct after microneedling, never injected, is a newer option with encouraging early evidence. A small open-label study in 16 men showed improved hair density at 12 months (Wan J et al., 2025 — PMID: 40146273). A broader review of exosome research, mostly preclinical with limited clinical data, found consistent density and thickness improvements across the studies it covered (Gupta AK et al., 2023 — PMID: 37381168). Neither source establishes this specifically in women yet. It's a promising, still-developing area, and the evidence base, while growing, is still early.
Who Should Have This Conversation
This applies to you if hair thinning started or worsened after beginning hormone therapy, if you've been told to simply lower your dose without anyone checking thyroid, ferritin, or stress load first, or if your results seem to differ from what a friend on a similar regimen describes.
What a Realistic Timeline Looks Like
Diffuse shedding from a corrected cause typically starts improving within two to three months, matching the hair cycle's own timeline, with regrowth visible several months beyond that. Androgen-directed treatments, minoxidil, PRP, spironolactone, or a 5-alpha-reductase inhibitor, generally need four to six months of consistent use before a fair assessment, with periodic monitoring built in for any prescription option.
If your hair loss started after beginning hormone therapy, the dose is one possible explanation among several, and it's worth ruling the others in or out before it's the one you act on.
Has anyone actually walked you through why your hair is thinning, or just told you to lower your dose and see what happens?
If you're already a patient at one of my clinics, this isn't asking you to switch, bring it up with your care team at your next visit. If you'd like an in-clinic consultation, here are all of the practices I see patients in. Prefer to start with a question first? Reach out directly by email or Instagram.
View My Clinic LocationsOr email drwilcox@precisionhormoneconsulting.com · DM @wellnessdoc_4everyoung on Instagram
— Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram
References
- Hillmer AM et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. American Journal of Human Genetics. 2005. PMID: 15902657. (Study population: men with early-onset pattern baldness; cited for AR gene biology applicable to the same receptor in women, not as female-specific data.)
- Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5α-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. Journal of Clinical Endocrinology & Metabolism. 2006;91(10):4085–4091. PMID: 16849416.
- Redler S et al. Selected variants of the steroid-5α-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified. Experimental Dermatology. 2012. PMID: 22509838.
- de Oliveira AFQ, Arcanjo FPN, Rodrigues MRP, Rosa e Silva AA, Hall PR. Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. Journal of Dermatological Treatment. 2023;34(1). PMID: 36264022.
- Ahmed KMA, Kozaa YA, Abuawwad MT, et al. Evaluating the efficacy and safety of combined microneedling therapy versus topical minoxidil in androgenetic alopecia: a systematic review and meta-analysis. Archives of Dermatological Research. 2025;317:528. PMID: 40056230.
- Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. Journal of Drugs in Dermatology. 2018;17(5):558.
- Wan J, Kim SB, Cartier H, Garson S, Frank K, Haykal D, Yi KH. A prospective study of exosome therapy for androgenetic alopecia. Aesthetic Plastic Surgery. 2025;49:3151–3156. PMID: 40146273. (Study population: 16 male patients, ages 36–45.)
- Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: preliminary evidence, safety, and future directions. Journal of Cosmetic Dermatology. 2023;22(9):2424–2433. PMID: 37381168. (Review of 16 studies, predominantly preclinical.)
This content is for educational purposes only and does not constitute medical advice. Hair loss has multiple possible causes, and an accurate diagnosis requires individualized lab evaluation and clinical exam. Finasteride and dutasteride, in any form, are contraindicated in pregnancy due to demonstrated fetal risk and require individualized discussion for any woman who could become pregnant. Spironolactone, finasteride, and dutasteride are used off-label for female pattern hair loss and require physician supervision and monitoring. Topical exosome treatments are applied topically only, not injected, and evidence for their use in hair restoration is still developing. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
